NasdaqCM - Nasdaq Real Time Price USD

Alpha Tau Medical Ltd. (DRTS)

2.8300
+0.0700
+(2.54%)
At close: May 14 at 4:00:00 PM EDT
Loading Chart for DRTS
  • Previous Close 2.7600
  • Open 2.8531
  • Bid 2.7900 x 100
  • Ask 2.8900 x 100
  • Day's Range 2.8200 - 2.9000
  • 52 Week Range 1.7500 - 4.3870
  • Volume 26,555
  • Avg. Volume 44,596
  • Market Cap (intraday) 239.109M
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.75

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

www.alphatau.com

125

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DRTS

View More

Performance Overview: DRTS

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DRTS
8.71%
S&P 500 (^GSPC)
0.19%

1-Year Return

DRTS
7.44%
S&P 500 (^GSPC)
12.31%

3-Year Return

DRTS
59.57%
S&P 500 (^GSPC)
46.44%

5-Year Return

DRTS
71.98%
S&P 500 (^GSPC)
106.58%

Compare To: DRTS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DRTS

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    239.11M

  • Enterprise Value

    192.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.82

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -23.27%

  • Return on Equity (ttm)

    -43.16%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -31.75M

  • Diluted EPS (ttm)

    -0.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    59.6M

  • Total Debt/Equity (mrq)

    20.00%

  • Levered Free Cash Flow (ttm)

    -12.97M

Research Analysis: DRTS

View More

Company Insights: DRTS

Research Reports: DRTS

View More

People Also Watch